Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced or metastatic urothelial cancer
2018-003636-79Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempegaldesleukin and nivolumab in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Nektar Therapeutics. Started Feb 2019; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2018-003636-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003636-79.